Theravance Biopharma (TBPH) Competitors $9.72 -0.25 (-2.51%) (As of 12:15 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TBPH vs. ANNX, PLRX, KNSA, IRON, NAMS, MNKD, HRMY, EVO, GPCR, and GLPGShould you be buying Theravance Biopharma stock or one of its competitors? The main competitors of Theravance Biopharma include Annexon (ANNX), Pliant Therapeutics (PLRX), Kiniksa Pharmaceuticals (KNSA), Disc Medicine (IRON), NewAmsterdam Pharma (NAMS), MannKind (MNKD), Harmony Biosciences (HRMY), Evotec (EVO), Structure Therapeutics (GPCR), and Galapagos (GLPG). These companies are all part of the "pharmaceutical preparations" industry. Theravance Biopharma vs. Annexon Pliant Therapeutics Kiniksa Pharmaceuticals Disc Medicine NewAmsterdam Pharma MannKind Harmony Biosciences Evotec Structure Therapeutics Galapagos Theravance Biopharma (NASDAQ:TBPH) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation, dividends and community ranking. Does the media favor TBPH or ANNX? In the previous week, Annexon had 14 more articles in the media than Theravance Biopharma. MarketBeat recorded 17 mentions for Annexon and 3 mentions for Theravance Biopharma. Annexon's average media sentiment score of 0.31 beat Theravance Biopharma's score of 0.28 indicating that Annexon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Theravance Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Annexon 2 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is TBPH or ANNX more profitable? Annexon has a net margin of 0.00% compared to Theravance Biopharma's net margin of -78.18%. Theravance Biopharma's return on equity of -24.79% beat Annexon's return on equity.Company Net Margins Return on Equity Return on Assets Theravance Biopharma-78.18% -24.79% -13.43% Annexon N/A -38.99%-33.90% Which has more volatility and risk, TBPH or ANNX? Theravance Biopharma has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500. Comparatively, Annexon has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500. Do analysts recommend TBPH or ANNX? Theravance Biopharma currently has a consensus price target of $13.75, indicating a potential upside of 41.46%. Annexon has a consensus price target of $15.80, indicating a potential upside of 195.33%. Given Annexon's stronger consensus rating and higher possible upside, analysts clearly believe Annexon is more favorable than Theravance Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Theravance Biopharma 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Annexon 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor TBPH or ANNX? Theravance Biopharma received 288 more outperform votes than Annexon when rated by MarketBeat users. However, 76.81% of users gave Annexon an outperform vote while only 62.80% of users gave Theravance Biopharma an outperform vote. CompanyUnderperformOutperformTheravance BiopharmaOutperform Votes34162.80% Underperform Votes20237.20% AnnexonOutperform Votes5376.81% Underperform Votes1623.19% Do insiders and institutionals hold more shares of TBPH or ANNX? 99.1% of Theravance Biopharma shares are held by institutional investors. 6.9% of Theravance Biopharma shares are held by company insiders. Comparatively, 12.7% of Annexon shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has higher valuation & earnings, TBPH or ANNX? Theravance Biopharma has higher revenue and earnings than Annexon. Theravance Biopharma is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTheravance Biopharma$57.42M8.32-$55.19M-$1.01-9.62AnnexonN/AN/A-$134.24M-$1.05-5.10 SummaryAnnexon beats Theravance Biopharma on 10 of the 17 factors compared between the two stocks. Ad Angel PublishingTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.Click here to get the details. Get Theravance Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TBPH vs. The Competition Export to ExcelMetricTheravance BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$477.93M$6.49B$5.09B$8.79BDividend YieldN/A8.11%5.04%4.07%P/E Ratio-9.625.3293.0914.02Price / Sales8.32370.921,220.6787.41Price / CashN/A52.5939.4936.27Price / Book2.5710.236.936.33Net Income-$55.19M$153.22M$118.83M$225.71M7 Day Performance1.57%-1.99%-1.74%-0.58%1 Month Performance12.24%-7.51%-3.60%1.49%1 Year Performance-5.45%31.02%31.91%27.23% Theravance Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TBPHTheravance Biopharma1.9174 of 5 stars$9.72-2.5%$13.75+41.5%-3.9%$477.93M$57.42M-9.62359ANNXAnnexon2.7832 of 5 stars$5.35+3.7%$15.80+195.3%+100.0%$570.26MN/A-5.1060Analyst RevisionPLRXPliant Therapeutics3.4847 of 5 stars$12.90+1.3%$40.57+214.5%-11.4%$784.97M$1.58M0.0090KNSAKiniksa Pharmaceuticals1.9939 of 5 stars$21.02-0.9%$36.60+74.1%+33.9%$1.52B$270.26M0.00220IRONDisc Medicine3.1676 of 5 stars$63.94+2.2%$85.80+34.2%+22.4%$1.90BN/A0.0078Insider TradeAnalyst RevisionNAMSNewAmsterdam Pharma2.9488 of 5 stars$20.44+2.1%$33.80+65.4%+110.6%$1.89B$14.09M0.0057Analyst ForecastInsider TradeNews CoverageMNKDMannKind3.47 of 5 stars$6.82-0.9%$8.67+27.1%+83.0%$1.88B$198.96M98.29400Insider TradeHRMYHarmony Biosciences4.7919 of 5 stars$32.81+0.1%$47.00+43.2%+18.1%$1.87B$582.02M15.64200EVOEvotec1.9292 of 5 stars$5.28-0.4%$5.93+12.4%-49.7%$1.87B$845.74M0.005,061GPCRStructure Therapeutics2.3001 of 5 stars$31.38-4.1%$86.80+176.6%-38.8%$1.80BN/A-42.84136Analyst RevisionGLPGGalapagos1.2835 of 5 stars$25.42-0.9%$30.75+21.0%-31.4%$1.68B$259.40M0.001,123Analyst DowngradeShort Interest ↓News Coverage Related Companies and Tools Related Companies ANNX Alternatives PLRX Alternatives KNSA Alternatives IRON Alternatives NAMS Alternatives MNKD Alternatives HRMY Alternatives EVO Alternatives GPCR Alternatives GLPG Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TBPH) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theravance Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theravance Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TBPH Stock Alerts